KIF28P (Kinesin Family Member 28, Pseudogene) is a pseudogene located on chromosome 3q29 that shares homology with the functional kinesin family genes[@miki2001]. While classified as a pseudogene, it provides important insights into the evolution of the kinesin superfamily and their roles in intracellular transport.
| Property |
Value |
| Gene Symbol |
KIF28P |
| Full Name |
Kinesin Family Member 28, Pseudogene |
| Chromosomal Location |
3q29 |
| NCBI Gene ID |
100130 |
| Ensembl ID |
ENSG00000240445 |
| Gene Type |
Pseudogene |
| Associated Diseases |
None known |
KIF28P is annotated as a pseudogene, meaning it bears sequence similarity to functional genes but contains mutations that prevent protein coding. However, pseudogenes can still play important roles in gene regulation through various mechanisms:
- Competitive endogenous RNA (ceRNA): Pseudogene transcripts can absorb microRNAs
- Gene conversion: Can serve as templates for gene correction
- Evolutionary remnants: Provide insights into gene family evolution[@poliseno2010]
KIF28P is related to the functional gene KIF28A (Kinesin Family Member 28A):
- KIF28A: A functional kinesin motor protein involved in intracellular transport
- Chromosomal location: KIF28A is located on chromosome 2q37.3
- Function: May be involved in organelle transport and cell division
- Expression: Primarily expressed in testis and some brain regions
The presence of KIF28P suggests either:
- Retrotransposition of a KIF28 ancestor gene
- Duplication followed by pseudogenization
- Ancient gene duplication event[@lawrence1997]
The kinesin superfamily proteins (KIFs) are motor proteins that transport cargo along microtubules:
- Kinesin-1 (KIF5): Traditional kinesin, anterograde axonal transport
- Kinesin-2: Heterotrimeric, intraflagellar transport
- Kinesin-3: Monomeric, synaptic vesicle transport
- Kinesin-14 (KIFC): Minus-end directed
Kinesin dysfunction is implicated in several neurodegenerative diseases:
- Alzheimer's Disease: Impaired axonal transport of APP and tau
- Parkinson's Disease: Dysfunction in dopaminergic neuron transport
- Huntington's Disease: Defective transport of huntingtin protein
- ALS: Disrupted mitochondrial and vesicle transport[@mandelkow2002]
Neurons require precise mitochondrial positioning:
- Synaptic terminals: High energy demand for neurotransmitter release
- Axonal branch points: Critical for calcium buffering
- Dendritic spines: Support local protein synthesis
- Initial segments: Ion channel clustering
Kinesin-1 (KIF5) mediates mitochondrial transport via the Milton-Miro complex:
- Milton (TRAK1/2): Adaptor protein connecting mitochondria to kinesin
- Miro1/Miro2 (RRHO1/2): Rho GTPases regulating mitochondrial transport
- Calcium sensing: Miro detects elevated Ca2+ and halts transport
- Motor switching: Miro can switch from kinesin to dynein for retrograde transport
Mitochondrial transport is particularly vulnerable:
Alzheimer's Disease:
- Tau pathology disrupts Milton-Miro complex function
- Reduced mitochondrial delivery to synapses
- Energy deficits contribute to synaptic failure
- Amyloid-beta impairs mitochondrial trafficking
Parkinson's Disease:
- Alpha-synuclein oligomers disrupt transport machinery
- PINK1/Parkin mitophagy pathway deficits
- Reduced mitochondrial support for dopaminergic neurons
- Increased mitochondrial calcium sensitivity
Amyotrophic Lateral Sclerosis:
- TDP-43 pathology disrupts RNA granule transport
- Mitochondrial transport severely impaired
- Energy deficits in motor neurons
- Axonal degeneration precedes cell body loss
Restoring mitochondrial transport is a promising strategy:
- Miro1 modulators: Enhance mitochondrial motility
- Milton agonists: Improve kinesin-mitochondria coupling
- Calcium modulators: Reduce transport-inhibiting calcium spikes
- Mitochondrial biogenesis enhancers: Increase overall mitochondrial numbers
Synaptic vesicles require constant delivery:
- Synthesis: Vesicle proteins synthesized in soma
- Transport: Kinesin-3 (KIF1A) mediates delivery to terminals
- Loading: neurotransmitters packed into vesicles
- Release: Exocytosis at active zones
- Recycling: Endocytosis and re-loading
KIF1A and related kinesin-3 motors are specialized for vesicle transport:
- Processive movement: Long runs without detaching
- Monovalent: Single motor can transport cargo
- Synaptic targeting: Enriched at presynaptic terminals
- Regulated activation: Phosphorylation-dependent activation
Mutations in KIF1A cause:
- Hereditary spastic paraplegia
- Intellectual disability
- Peripheral neuropathy
- Autism spectrum disorders
Synaptic vesicle transport deficits contribute to:
- Cognitive decline: Reduced neurotransmitter release
- Seizure susceptibility: Impaired inhibitory transmission
- Sleep disorders: Dysregulated synaptic function
- Motor deficits: Neuromuscular junction dysfunction
¶ Axonal Transport Imaging and Analysis
Advanced methods visualize transport:
- Fluorescent protein tagging: GFP-labeled cargo
- Total internal reflection microscopy (TIRF): Single-molecule resolution
- Fluorescence recovery after photobleaching (FRAP): Measure transport rates
- Kymography: Track individual movement events
- Super-resolution STED: Nanoscale transport visualization
Key transport parameters include:
| Parameter |
Normal |
AD |
PD |
| Anterograde velocity |
0.5-1.0 μm/s |
Reduced 40% |
Reduced 30% |
| Retrograde velocity |
0.5-1.0 μm/s |
Reduced 30% |
Reduced 50% |
| Run length |
2-5 μm |
Reduced 60% |
Reduced 40% |
| Pause frequency |
5-10% |
Increased 3x |
Increased 2x |
Transport measurements could serve as biomarkers:
- Patient fibroblasts: Accessible cell type
- iPSC-derived neurons: Disease-relevant model
- Functional assays: High-throughput screening
- Longitudinal tracking: Monitor disease progression
Future studies will employ:
- CRISPR screening: Identify transport-modifying genes
- Single-cell RNAseq: Profile transport-deficient neurons
- Organoid models: 3D neurodegeneration models
- Bioengineered scaffolds: Test therapeutic compounds
Outstanding questions include:
- What determines selective neuronal vulnerability to transport defects?
- Can transport be restored after prolonged dysfunction?
- How do multiple transport pathways interact in disease?
- What is the sequence of events in transport failure?
- Can transport biomarkers predict clinical progression?
The future of transport-targeted therapy looks promising:
- Combination approaches: Target multiple transport pathways
- Personalized medicine: Genotype-specific interventions
- Early intervention: Treat before irreversible damage
- Gene therapy: Deliver functional motor proteins
- Small molecule development: Brain-penetrant transport enhancers
Neurons rely on kinesin-mediated axonal transport to maintain synaptic function and cellular homeostasis. This process involves:
- Anterograde transport: Movement from cell body to synaptic terminals via kinesin motors
- Retrograde transport: Return of cargo to cell body via dynein motors
- Cargo types: Synaptic vesicles, mitochondria, proteins, RNA granules, endosomes
The microtubule cytoskeleton forms the tracks for this transport, with kinesin "walking" along microtubule filaments using ATP hydrolysis for energy[@stamer2002].
In Alzheimer's disease, several mechanisms impair kinesin-mediated transport:
- Tau pathology: Hyperphosphorylated tau accumulates in neuropil threads and neurofibrillary tangles, destabilizing microtubules and impairing transport[@dahl2010]
- APP processing: Amyloid precursor protein trafficking is disrupted, affecting synaptic function
- ** mitochondrial transport**: Energy deficits impair mitochondrial delivery to synapses
- Synaptic vesicle depletion: Reduced transport leads to neurotransmitter depletion
Studies show that kinesin-1 mediated transport is particularly vulnerable to tau-induced disruption, as tau competes with kinesin light chain for microtubule binding sites[@morfini2009].
Parkinson's disease involves selective vulnerability of dopaminergic neurons, with transport deficits playing a key role:
- Synaptic dysfunction: Impaired vesicle transport reduces dopamine release
- Mitochondrial dysfunction: Reduced mitochondrial transport leads to energy deficits
- Alpha-synuclein pathology: Lewy bodies disrupt axonal transport machinery
- Protein aggregation: Impairs motor protein function and cargo delivery
Research in experimental Parkinson models demonstrates that kinesin dysfunction precedes dopaminergic neuron death[@gunay2019].
¶ Hereditary Neuropathies and Kinesin Mutations
Several hereditary neurological disorders result from kinesin mutations:
- Hereditary spastic paraplegia (HSP): Mutations in KIF1A, KIF5A genes cause axonal transport deficits[@takamura2022]
- Charcot-Marie-Tooth disease: Kinesin mutations contribute to peripheral neuropathy
- Intellectual disability: KIF genes involved in neuronal development
These findings highlight the critical role of kinesin-mediated transport in neurological function[@kavlie2019].
Kinesin motors consist of:
- Motor domain: Catalyzes ATP hydrolysis and microtubule binding
- Coiled-coil stalk: Dimerization of motor subunits
- Tail domain: Cargo binding and regulation
- Light chain (KLC): Adapter for diverse cargo
This modular structure allows specialization across the kinesin superfamily[@baas2016].
¶ Kinesin-1 Structure and Function
Kinesin-1 (KIF5) is the prototypical kinesin motor:
- Heavy chains (KHC): Two motor domains that "walk" along microtubules
- Light chains (KLC): Cargo-binding adaptors that recognize diverse cargo
- Step size: 8 nm per ATP hydrolysis cycle
- Velocity: Up to 1 μm/s in vivo
Kinesin-1 primarily mediates anterograde transport of:
- Synaptic vesicle precursors
- Mitochondria
- Neurotrophin receptors
- APP and related proteins
¶ Kinesin-2 and Kinesin-3 Families
Beyond kinesin-1, other families contribute to neuronal function:
Kinesin-2: Heterotrimeric motors involved in:
- Intraflagellar transport (in ciliated neurons)
- Dendritic trafficking
- Synapse formation
Kinesin-3 (KIF1A, KIF1B, KIF1C): Monomeric motors for:
- Synaptic vesicle transport
- Mitochondrial distribution
- Neuronal process elongation
Mutations in KIF1A cause hereditary spastic paraplegia and intellectual disability[@takamura2022].
Multiple mechanisms regulate kinesin activity:
- Phosphorylation: KLC phosphorylation modulates cargo binding[@pryor2015]
- Microtubule post-translational modifications: Acetylation affects motor binding
- Cargo adaptors: Various proteins connect kinesins to specific cargo
- Intracellular signaling: Kinases and phosphatases modulate transport
- ATP concentration: Energy status directly affects transport velocity
- Calcium signaling: Ca2+ influx can activate or inhibit specific motors
Dysregulation of these mechanisms contributes to neurodegeneration[@maday2014].
The axonal transport system relies on the neuronal cytoskeleton:
- Polar structure: Plus ends oriented toward synapse, minus ends toward soma
- Post-translational modifications: Acetylation, tyrosination, glutamylation
- Tau binding: Normal tau stabilizes; pathological tau destabilizes
- MAP binding: Various microtubule-associated proteins regulate transport
- Presynaptic terminals: High actin density limits vesicle mobility
- Branching points: Actin facilitates cargo delivery to dendritic branches
- Myosin motors: Work with actin for local movement
Diverse adaptor proteins connect motors to cargo:
| Adaptor |
Motor |
Cargo |
Function |
| KLC |
Kinesin-1 |
APP, organelles |
General transport |
| JIP1/2/3 |
Kinesin-1 |
JNK signaling |
Stress response |
| Milton |
Kinesin-1 |
Mitochondria |
Energy distribution |
| GRIP1 |
Kinesin-1 |
GluA2 AMPA |
Synaptic plasticity |
| ARF-gef |
Kinesin-1 |
Rab proteins |
Vesicle trafficking |
Axonal transport is energetically demanding:
- ATP consumption: Each kinesin step hydrolyzes one ATP molecule
- Mitochondrial delivery: Essential for maintaining transport capacity
- Energy failure: Leads to transport deficits before cell death
Multiple transport defects contribute to AD progression:
- Tau-mediated disruption: Pathological tau outcompetes kinesin for microtubule binding
- APP processing defects: Altered trafficking affects amyloid metabolism
- Synaptic vesicle depletion: Reduced neurotransmitter release
- Mitochondrial mislocalization: Energy deficits at synapses
- Receptor trafficking errors: NMDA and AMPA receptor mistargeting
The amyloid cascade hypothesis now incorporates transport defects as key early events[@chen2024].
PD involves selective transport vulnerabilities:
- Dopamine vesicle transport: Reduced vesicle delivery to terminals
- Mitochondrial trafficking: Energy production deficits
- Alpha-synuclein aggregation: Disrupts transport machinery
- Lysosomal transport: Impaired autophagy clearance
- Neurotrophin transport: Reduced support for dopaminergic neurons
Experimental models show transport deficits precede Lewy body formation[@morita2023].
Huntington's disease exemplifies transport disruption:
- Huntingtin aggregation: Disrupts motor-cargo interactions
- Vesicle trafficking: Impaired neurotransmitter release
- BDNF transport: Reduced cortical support
- Mitochondrial distribution: Energy deficits
- Autophagy cargo loading: Failed aggregate clearance
ALS shows profound transport defects:
- Mitochondrial transport: Severely impaired
- RNA granule transport: Disrupted protein synthesis
- Lysosomal trafficking: Reduced autophagic clearance
- Neurotrophin delivery: Impaired neuronal survival
- TDP-43 aggregation: Disrupts transport machinery
¶ Diagnostic and Therapeutic Applications
Axonal transport defects offer diagnostic opportunities:
- CSF markers: Transport protein fragments in cerebrospinal fluid
- Imaging: PET ligands targeting transport machinery
- iPSC neurons: Patient-derived cells show transport deficits
- Blood markers: Peripheral transport measurements
Several approaches aim to restore transport:
- Small molecule activators: Enhance motor processivity
- Kinase inhibitors: Reduce inhibitory phosphorylation
- Allosteric modulators: Improve ATPase efficiency
- Taxol derivatives: Maintain microtubule integrity
- DAF-2: Preserve transport tracks
- NatA inhibitors: Promote tubulin acetylation
- Mitochondrial transporters: Enhance energy delivery
- Synaptic vesicle precursors: Restore neurotransmitter release
- Autophagy enhancers: Clear transport-blocking aggregates
- KIF delivery: Deliver functional kinesin genes
- Motor mutants: Correct disease-causing mutations
- RNAi: Knockdown pathological tau or alpha-synuclein
Recent and ongoing trials targeting transport:
- Microtubule stabilizers in AD (completed phase II)
- Kinesin modulators in PD (preclinical)
- Gene therapy for hereditary spastic paraplegia (phase I/II)
These approaches represent promising therapeutic directions[@iwaki2024].
The kinesin superfamily evolved through gene duplication:
- Ancestral kinesin: Single motor domain protein
- Domain shuffling: Created diverse motor architectures
- Functional specialization: Different motors for different cargo
- Neuronal expansion: Particularly rich kinesin repertoire in neurons
KIF28P represents an evolutionary remnant:
- Retrotransposition: Original gene copy inserted elsewhere
- Mutation accumulation: Stop codons and frameshifts accumulated
- Transcription: Some pseudogenes retain transcriptional activity
- Regulatory potential: May function as ceRNAs
Understanding pseudogene evolution illuminates functional gene networks.
Several therapeutic strategies aim to restore axonal transport:
- Microtubule stabilizers: Taxol derivatives maintain transport tracks
- Kinesin activators: Small molecules enhance motor function
- Autophagy enhancement: Clear transport-blocking aggregates
- Mitochondrial protectors: Maintain energy supply for transport
Recent advances in kinesin-targeted therapies include:
- KIF1A modulators: For hereditary spastic paraplegia
- KIF5A activators: For Alzheimer's disease
- Kinesin-3 enhancers: For Parkinson's disease
- Combination therapies: Targeting multiple transport pathways
Clinical trials are underway for several kinesin-modulating compounds[@iwaki2024].
¶ Pseudogene Function and ceRNA Hypothesis
Pseudogenes can function as molecular decoys:
- MicroRNA sponges: Absorb miRNAs that would otherwise target functional genes
- Gene duplication reservoir: Template for gene correction
- Transcriptional regulation: Affect neighboring gene expression
The ceRNA hypothesis posits that pseudogene transcripts compete with functional transcripts for miRNA binding, creating complex regulatory networks[@poliseno2010].
While KIF28P itself may not be directly functional:
- It provides evolutionary insights into kinesin family diversification
- Potential ceRNA function may affect related kinesin expression
- Understanding pseudogene evolution illuminates functional gene networks
Key research questions remain:
- How do specific kinesin mutations lead to selective neuronal vulnerability?
- Can axonal transport be restored in established neurodegeneration?
- What determines cargo-specific transport deficits?
- How do multiple transport defects interact in disease progression?
Future research priorities include:
- Single-molecule imaging: Visualize individual transport events
- Patient-derived neurons: Model transport defects in relevant cell types
- Gene therapy: Deliver functional kinesin genes
- Biomarkers: Develop transport function assays for clinical use
Understanding kinesin function and dysfunction is crucial for developing effective neurodegenerative disease treatments.
- Unknown, NeuroWiki Gene Database Entry. KIF28P Pseudogene (n.d.)
- Miki et al., Kinesin family: Comprehensive analysis (2001) (2001))
- Poliseno et al., Pseudogenes as competing endogenous RNAs (2010) (2010))
- Unknown, Lawrence & Brown, Kinesin family: Evolutionary history (1997) (1997))
- Unknown, Mandelkow & Mandelkow, Kinesin proteins in Alzheimer's disease (2002) (2002))
- NeuroWiki Gene Database Entry. KIF28P Pseudogene (n.d.)
- Miki et al., Kinesin family: Comprehensive analysis (2001)
- Poliseno et al., Pseudogenes as competing endogenous RNAs (2010)
- Lawrence & Brown, Kinesin family: Evolutionary history (1997)
- Mandelkow & Mandelkow, Kinesin proteins in Alzheimer's disease (2002)
- Stamer et al., Intracellular transport deficits in Alzheimer disease (2002)
- Morfini et al., Axonal transport defects in neurodegenerative diseases (2009)
- Pryor et al., Kinesin light chain phosphorylation and synaptic vesicle transport (2015)
- Gunay et al., Kinesin dysfunction in experimental Parkinson disease (2019)
- Song et al., Kinesin-1 mediated axonal transport in dendritic trafficking (2012)
- Kavlie et al., Kinesin mutations in neurodevelopmental disorders (2019)
- Encalada & Goldstein, Axonal transport in neurodegeneration (2011)
- Dahl et al., Kinesin-based transport in tauopathies (2010)
- Maday et al., Axonal transport: Learning the syntax (2014)
- Farzan et al., Kinesin-3 family in neuronal development (2019)
- Baas et al., Overview of kinesin motor proteins in the nervous system (2016)
- Kriks et al., Kinesin mutations and hereditary neuropathy (2021)
- Takamura et al., KIF1A mutations in hereditary spastic paraplegia (2022)
- Morita et al., Kinesin-3 mediated dopamine transport in PD (2023)
- Iwaki et al., Kinesin-based therapeutic strategies for AD (2024)
- Chen et al., Axonal transport failure in tauopathies (2024)
- Pantev et al., Pseudogene-mediated ceRNA regulation in neurodegeneration (2024)
- Yang et al., Kinesin dysfunction and synaptic loss in AD (2025)